The purpose of the operation with Fundacao Butantan ("Client" or "Butantan") is to finance the construction of two new pharmaceutical manufacturing and processing units: i) the Egg-based Vaccine Research Center ("CPVO II"), which consists of an Influenza vaccine manufacturing plant; and ii) the Final Processing Center for Immunobiologicals ("CPFI"), which consists of a plant for formulating, filling, lyophilizing, crimping, labeling, and packaging pharmaceutical products ("Project").
The operation will be structured in the form of a loan, with a final term of 10 years, including a 3-year grace period. The project will be developed in the City of Sao Paulo, Brazil, at the same location where Fundacao Butantan currently operates.
Addendum: On November 7, a revised version is uploaded for the Environmental and Social Impact Study.
ACCESS TO INFORMATION
You can submit a request for information disclosure at:
ACCOUNTABILITY MECHANISM OF IDB / IDB INVEST
The Independent Consultation and Investigation Mechanism (MICI) is the independent complaint mechanism and fact-finding body for people who have been or are likely to be adversely affected by an Inter-American Development Bank (IDB) or Inter-American Investment Corporation (IDB Invest)-funded project. If you submit a complaint to MICI, they may assist you in addressing the problems you raised through a dispute-resolution process with those implementing the project and/or through an investigation to assess whether the IDB or IDB Invest is following its own policies for preventing or mitigating harm to people or the environment. You can submit a complaint by sending an email to MICI@iadb.org. You can learn more about the MICI and how to file a complaint at http://www.iadb.org/en/mici/mici,1752.html (in English) or http://www.iadb.org/es/mici/mici,1752.html (Spanish).